Share on StockTwits

Tekmira Pharmaceuticals (NASDAQ:TKMR) was the recipient of a significant drop in short interest during the month of June. As of June 30th, there was short interest totalling 804,797 shares, a drop of 22.3% from the June 13th total of 1,036,358 shares, StockRatingsNetwork reports. Currently, 4.0% of the shares of the company are short sold. Based on an average daily trading volume, of 222,427 shares, the days-to-cover ratio is currently 3.6 days.

Several analysts have recently commented on the stock. Analysts at Maxim Group cut their price target on shares of Tekmira Pharmaceuticals from $29.00 to $23.00 in a research note on Wednesday, June 4th. They now have a “buy” rating on the stock. Analysts at Stifel Nicolaus reiterated a “buy” rating on shares of Tekmira Pharmaceuticals in a research note on Thursday, May 15th. They now have a $31.00 price target on the stock, down previously from $37.00.

Shares of Tekmira Pharmaceuticals (NASDAQ:TKMR) opened at 9.57 on Tuesday. Tekmira Pharmaceuticals has a one year low of $4.85 and a one year high of $31.48. The stock’s 50-day moving average is $12.35 and its 200-day moving average is $15.50.

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing ribonucleic acid (NASDAQ:TKMR) interference (RNAi) therapeutics and providing its lipid nanoparticle (LNP) delivery technology to pharmaceutical partners.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.